# Sermorelin Telehealth — Editorial Compendium of the GHRH(1-29) Research Literature > An Art Nouveau reading room for the sermorelin literature — GHRH(1-29) mechanism, the Geref chapter, the 503A compounding pathway that telemedicine operates within, and the IGF-1 biomarker rhythm. A bound editorial compendium of the peer-reviewed literature on GHRH(1-29) — the 29-amino-acid signaling fragment behind the pulsatile, sleep-coupled growth-hormone rhythm. The Geref chapter, the 503A compounding pathway, and the IGF-1 biomarker that adult research turns on. No prescriptions are written here; only the literature is read. ## The short version Sermorelin is a 29-amino-acid synthetic fragment of the body's own growth hormone-releasing hormone (GHRH). It binds the same pituitary receptor that natural GHRH uses, prompting the gland to fire a brief, self-limiting pulse of growth hormone — the kind the body fires naturally during deep sleep. Because the pulse is governed by the same somatostatin and IGF-1 feedback that controls all other GH secretion, sermorelin cannot push growth hormone into supraphysiologic territory the way direct GH injections can. It was once an FDA-approved drug (Geref, 1997–2008) for children with growth hormone deficiency, withdrawn for commercial reasons, not for any safety or effectiveness problem. Today it is compounded by licensed pharmacies under the 503A pathway. This compendium reads the peer-reviewed literature on sermorelin's mechanism, its Geref chapter, the adult and cognitive research, and the regulatory context — it does not prescribe, dispense, or advise. See [what people in research-use communities report on the effects page](/effects). ## What sermorelin is, in one careful paragraph Sermorelin is the synthetic acetate salt of the first 29 amino acids of human growth hormone-releasing hormone — a fragment that retains, in published binding studies, essentially the full biological activity of the parent 44-residue hormone [1]. It binds the GHRH receptor on anterior-pituitary somatotrophs and triggers a brief, physiologic pulse of endogenous growth hormone [1]. The receiving cell is the same somatotroph the body has been using for its own pulsatile signaling since adolescence; sermorelin does not introduce exogenous hormone, it coaxes the pituitary to fire a single pulse it would, under sufficient endogenous GHRH tone, have fired anyway. The pharmacology that follows from this is unusual. Because intact somatostatin tone and rising IGF-1 negative feedback both close the loop, sermorelin-driven growth-hormone release is self-limiting and pulsatile — the opposite of the continuous receptor occupancy produced by recombinant human growth hormone injections [20]. Plasma half-life is approximately eleven to twelve minutes [6]. By design, each subcutaneous dose produces one discrete physiologic pulse rather than sustained elevation. This is the architectural feature that distinguishes the GHRH-agonist class from direct GH replacement, and it is the feature the older adult-research literature returns to most often [20]. ## Why this compendium exists Sermorelin occupies an unusual position in the contemporary pharmacology of the GH/IGF-1 axis. It is the rare compound that holds a historical FDA approval — the Geref new drug application (NDA 020443) was approved in 1997 for pediatric idiopathic growth-hormone deficiency [1] — yet has no FDA-approved finished product on the U.S. market in 2026. The manufacturer voluntarily discontinued Geref in 2008 for commercial and manufacturing-process reasons; the FDA's March 4, 2013 Federal Register determination (78 FR 14114) expressly affirmed that the withdrawal was not for reasons of safety or effectiveness [18]. That regulatory finding is the legal predicate for ongoing 503A and 503B pharmacy compounding of sermorelin in the United States. The internet's writing on the subject is, by and large, written by parties who sell the compounded product, who provide the telemedicine consultation that supplies the prescription, or who oppose both. The literature deserves a reading that is none of those — a quiet bound volume that summarizes what the peer-reviewed studies have actually established and what they have not. This site is that volume. ## The story the literature tells, briefly The published research on sermorelin (and on the structurally related GHRH analogs that form its pharmacologic siblings) tells four overlapping stories. The first story is pediatric. In the pivotal multicenter trial supporting the original FDA approval, one hundred and ten prepubertal children with idiopathic growth-hormone deficiency receiving thirty micrograms per kilogram of subcutaneous sermorelin nightly at bedtime saw mean height velocity rise from 4.1 centimeters per year at baseline to 8.0 at six months and 7.2 at twelve months — and seventy-four percent of the children were classified as good responders at the six-month mark [1]. The second story is adult somatopause. A two-week study at the National Institute on Aging in 1992 showed that GHRH(1-29) at half a milligram to one milligram twice daily restored mean twenty-four-hour growth hormone and IGF-1 in healthy older men to values statistically indistinguishable from those of healthy young controls [2]. A 1997 sixteen-week trial of a closely related GHRH analog at ten micrograms per kilogram nightly produced approximately a 1.26-kilogram lean-mass gain in men, improved insulin sensitivity, and increased skin thickness in both sexes [3]. The third story is cognition. A twenty-week placebo-controlled trial at the University of Washington in 2012 administered one milligram nightly of tesamorelin (a stabilized GHRH analog of the same mechanistic class) to one hundred and thirty-seven older adults — some with mild cognitive impairment, some healthy — and showed significant improvement in executive function (p = .005) [4]. Magnetic-resonance spectroscopy at the trial's end documented increased GABA in all three brain regions assayed and decreased myo-inositol in the posterior cingulate — a measurable neurochemical signature beneath the cognitive signal [5]. An earlier randomized trial in 2006 with GHRH(1-29) over six months produced a similar executive-function signal, most pronounced in subjects with lower baseline cognitive scores [16]. The fourth story is recent and structural. A 2025 review in Reviews in Endocrine and Metabolic Disorders catalogued GHRH-class cardioprotection — restored phospholamban phosphorylation, improved diastolic function, attenuated post-MI cardiac hypertrophy in preclinical models [9]. A 2024 synthesis by Andrew Schally and colleagues consolidated the expanding therapeutic landscape of GHRH analogs across wound healing, beta-cell preservation, and neuroprotection [11]. The receptor through which sermorelin acts is, on the evidence of the last decade, more interesting than the pituitary alone would suggest. ## The telehealth chapter of the story Sermorelin has become culturally legible, in the 2020s, as a telemedicine compound. This is not because the literature changed; it is because the delivery mechanism for the literature did. With no FDA-approved finished sermorelin product on the U.S. market since 2008, the pharmacy infrastructure that supplies adult research and clinical use is the 503A and 503B compounding pathway — a corridor that fits comfortably with the telemedicine prescription-by-video model that expanded after 2020. A 2024 European review of adult growth-hormone deficiency confirmed what the regulatory landscape made obvious: the post-2008 worldwide unavailability of pharmaceutical GHRH has materially changed adult GHD diagnostic and clinical practice, and standard provocation tests using pharmaceutical GHRH are 'no longer feasible' through ordinary supply [12]. The compounded compendium is, at present, the substrate. This site reads the literature about that substrate — it does not provide telemedicine services, does not prescribe, does not dispense, and is not affiliated with any pharmacy or clinic. ## What you will find in the chapters that follow The /research chapter (§ II) walks the mechanism in greater detail — the GHRH receptor, the cAMP/PKA cascade, the pulsatile architecture, and what the published trials actually measured. The /dosage chapter (§ III) describes the dose figures used in published studies and in the historical Geref label, framed as research context rather than guidance; the IGF-1 biomarker rhythm sits here. The /effects chapter (§ VII) presents what research-use communities report — benefits, adverse effects, and the safety cautions grounded in the literature. The /faq chapter (§ IV) answers the questions that recur in the consumer-facing literature about sermorelin telehealth. The /references chapter (§ V) is the apparatus — full citations, PubMed identifiers, DOIs. The /about and /contact chapters describe the publisher and the reader's correspondence channel. --- An ornamented editorial compendium of the published research — not a clinic, not a vendor, not a prescription.